As an investor, deciding whether the IPO is Good or Bad to invest in can often be challenging. If you are confused and worried about whether to Apply or Not the Amanta Healthcare IPO. Then worry not, here we are describing 10 important key points & an in-depth, detailed Amanta Healthcare IPO review which will help you to make the decision.
Strengths and Weaknesses of Amanta Healthcare IPO
Strengths:
- Amanta Healthcare is a well-established manufacturer of pharmaceutical formulations with a wide product range and presence in diverse markets.
- The company includes an experienced management team and promoters who have over 30 years of experience in the pharmaceutical industry.
- The company comprises of having a large manufacturing capability spread over 66,852.00 sq meters of land located at village Hariyala, District Kheda, Gujarat, India.
Weaknesses:
- It’s all products made at the manufacturing facility are located at Hariyala village, Kheda district, Gujarat. Any delay or shutdown at the facility due to issues like power or water shortage, natural disaster, accidents, or machinery breakdowns can badly impact the business, cash flow, and financial condition.
- The company may not be able to improve its profit margins and profits in the future.
- In FY 2025, 45.78%, 57.25% in FY 2024, and 62.64% in FY 2023, the company’s finance cost has been very high. Meaning if the company does not reduce these costs in the future, then it can badly impact the business, financial condition, and cash flow.
- In the past, their manufacturing license was suspended. If suspensions happen again in the future can negatively impact the business, cash flow, and financial condition.
Amanta Healthcare IPO Review
- IPO Watch: May Apply
- Invest4Edu Private Limited: Apply
- Scoop Investment: May Apply
- Exencial Research Partners: May Apply
- Minerva Capital Research Solutions: May Apply
- Capital Market: Avoid
Amanta Healthcare IPO Details
| IPO Size | ₹126 crores |
| Offer-for-sale | No Offer-for-Sale |
| Fresh issue | ₹126 crores |
| Price band | ₹120 to ₹126 |
| Subscription | Opens on September 1, 2025, and the closing date is September 3, 2025 |
| Purpose of IPO | Fresh Issue and No Offer-for-Sale |
Amanta Healthcare IPO Open and closing dates?
Amanta Healthcare IPO will open for subscription on September 1, 2025, and will be closed for subscription on September 3, 2025.
What is the size of the Amanta Healthcare IPO?
The company planned to raise around ₹126 crores in funds via IPO. This IPO comprises a fresh issue of ₹126 crores with no Offer-for-Sale component with a face value of ₹10 each.
What are the subscription details of the Amanta Healthcare IPO?
The Amanta Healthcare IPO price range is set at ₹120 to ₹126 per share. In this IPO, a total of 119 shares were available in 1 lot size for the minimum Retail category. For the maximum Retail category, 1,547 shares were available in 13 lot sizes. Additionally, 1,666 shares were available in 14 lot sizes for the S-HNI Minimum category. While for the B-HNI Minimum category, 7,973 shares were available in 67 lot sizes.
To invest in this IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum investment of ₹14,994 and maximum investment of ₹1,94,922.
- Small HNI (S-HNI): Minimum investment of ₹2,09,916.
- Big HSI (S-HNI): A minimum investment of ₹10,04,598 is required.
What is the Amanta Healthcare IPO listing Date?
Amanta Healthcare is a Mainboard IPO. Shares will be listed on September 8, 2025, on the BSE (Bombay Stock Exchange) & NSE (National Stock Exchange).
About Amanta Healthcare
Incorporated in December 1994, Amanta Healthcare Limited is one of the growing pharmaceutical companies engaged in the development, manufacturing, and marketing of a comprehensive range of sterile liquid products, mainly parenterals. The company is involved in the making of IV fluids, diluents, eye drops, and respiratory care solutions. These are packed in plastic containers using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies.
As of March 31, 2025, the company employs a total of 1,718 employees. Under its medical devices segment, Amanta Healthcare also offers irrigation solutions, first-aid items, and eye lubricants. Under its own brand, the company makes over 45 generic products and sells them in India, through 320 distributors and stockists.
What are the Objectives of the Amanta Healthcare Limited IPO?
The proceeds raised from the fresh issue will be utilized to handle the capital expenditure requirements for civil construction work and towards the purchase of equipment, plant, and machinery for setting up a new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat. Some proceeds will be used towards civil construction work, purchase of equipment, plant, and machinery, and setting up a new manufacturing line for SVP at Hariyala, Kheda, Gujarat. Lastly, the remaining funds will be used for the company’s General Corporate Purposes.
Amanta Healthcare IPO Financials
In 2024, the company generated a revenue of ₹13,946.01 crores against ₹2,690.46 crores in 2023. In 2024, reported a profit of ₹5,245.39 crores against a profit of ₹231.11 crores in 2023.
Amanta Healthcare IPO Promoters
Bhavesh Patel, Vishal Patel, Jayshreeben Patel, Jitendra Kumar Patel, and Milcent Appliances Private Limited are the promoters of the company.
Who are the Amanta Healthcare IPO lead managers and registrar?
Beeline Capital Advisors Pvt Limited is the issue’s lead manager, while MUFG Intime India Pvt Ltd is the company’s registrar.
Should you apply or not for the Amanta Healthcare IPO?
Amanta Healthcare is launching an IPO that is comprised of only a fresh issue, with no offer-for-sale component. The company has set a price band of ₹120 to ₹126 per share and a plan to raise around ₹126 crores via IPO. It is one of the leading pharmaceutical companies engaged in the development, manufacturing & marketing of a wide range of Sterile Liquid products. As of the DRHP filing date, the company has a portfolio of 47 products across 120 international jurisdictions.
If we talk about the company’s financials, in FY25, Amanta reported an EBITDA of ₹59.7 crore, showcasing a rise of 3.8% from the previous year. The proceeds raised from the fresh issue will be utilized for the funding of new manufacturing lines and other corporate needs. The company incorporates technologies, including ABFS and ISBM, for sterile liquid and parenteral formulations production. Expanding the National Sales network, increasing business from existing customers, and adding new customers are some of the strategies the company will be following in the future.
So, now the question is, should you apply or not for the Amanta Healthcare IPO? If you are looking to invest in a company that promotes client relationships, a highly diversified customer base, and a proven track record of consistent growth, Rising EBITDA and margins signal stronger operating efficiency, then Amanta Healthcare’s IPO could be a good long-term investment option.
However, we recommend always doing a good financial background check on the company you want to invest in, and investing in it at your own risk.
